Ishida Hiroyuki, Watanabe Shuichi, Rodriguez Franco Salvador, Franklin Oskar, Stoop Thomas F, Kirsch Michael J, Schulick Richard D, Del Chiaro Marco
Division of Surgical Oncology, Department of Surgery, University of Colorado School of Medicine, Aurora, Colorado, USA.
Department of Hepatobiliary and Pancreatic Surgery, Institute of Science Tokyo, Tokyo, Japan.
Ann Surg. 2024 Dec 16. doi: 10.1097/SLA.0000000000006605.
To investigate the incidence and risk factors of portomesenteric venous thrombosis (PVT) after pancreatic cancer surgery with portomesenteric venous resection (PVR).
Pancreatic cancer surgery with PVR can be complicated by PVT, but the long-term associations, risk factors, and consequences of PVT have not been clearly elucidated.
This study included pancreatic cancer patients undergoing any type of pancreatic resection with PVR at the University of Colorado Hospital between January 2012 and June 2023. The study period was divided based on the implementation of local standardization of PVR techniques in August 2018. PVT was classified as early or late (≤ or >30 d postoperatively). Risk factors for late PVT were assessed with Cox regression models.
Among 152 patients, 3.3% (n=5) developed early PVT. Its incidence decreased from 12% (n=3/25) to 1.6% (n=2/127) after technical standardization (P=0.03). Of 130 patients with available postoperative imaging, 21.5% (n=28) developed late PVT at a median of 7.4 months from surgery. Late PVT was frequently diagnosed with local recurrence (75%) and was associated with shorter recurrence-free survival (median 9.0 vs. 16.3 mo, P=0.014). Multivariable analysis showed that neoadjuvant radiotherapy (hazard ratio [HR], 2.19; 95% CI, 1.02-4.67) and local recurrence (HR, 5.21; 95% CI, 2.18-12.4) were associated with an increased risk of late PVT.
Early PVT after pancreatectomy with PVR is rare. Late PVT is associated with neoadjuvant radiotherapy and local recurrence. These findings may inform risk assessment in pancreatic cancer patients undergoing PVR.
探讨胰腺癌手术联合门静脉肠系膜静脉切除(PVR)后门静脉肠系膜静脉血栓形成(PVT)的发生率及危险因素。
胰腺癌手术联合PVR可能并发PVT,但PVT的长期关联、危险因素及后果尚未明确阐明。
本研究纳入2012年1月至2023年6月在科罗拉多大学医院接受任何类型胰腺癌切除联合PVR的患者。研究期根据2018年8月PVR技术的局部标准化实施情况进行划分。PVT分为早期或晚期(术后≤或>30天)。采用Cox回归模型评估晚期PVT的危险因素。
152例患者中,3.3%(n=5)发生早期PVT。技术标准化后其发生率从12%(n=3/25)降至1.6%(n=2/127)(P=0.03)。130例有术后影像学资料的患者中,21.5%(n=28)发生晚期PVT,中位时间为术后7.4个月。晚期PVT常被诊断为局部复发(75%),且与无复发生存期较短相关(中位时间9.0个月对16.3个月,P=0.014)。多变量分析显示,新辅助放疗(风险比[HR],2.19;95%置信区间,1.02-4.67)和局部复发(HR,5.21;95%置信区间,2.18-12.4)与晚期PVT风险增加相关。
胰腺癌切除联合PVR术后早期PVT罕见。晚期PVT与新辅助放疗和局部复发相关。这些发现可能为接受PVR的胰腺癌患者的风险评估提供参考。